(Q28243031)

English

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

scientific article (publication date: February 2012)

In more languages

Statements

scholarly article

0 references

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study (English)

0 references

0 references

attention deficit hyperactivity disorder

0 references

1 reference

based on heuristic

inferred from title

author name string

George Apostol

1

0 references

Walid Abi-Saab

2

0 references

Christopher J Kratochvil

3

0 references

Lenard A Adler

4

0 references

Weining Z Robieson

5

0 references

Laura M Gault

6

0 references

Yili L Pritchett

7

0 references

David Feifel

8

0 references

Michelle A Collins

9

0 references

Mario D Saltarelli

10

0 references

language of work or name

0 references

publication date

February 2012

0 references

Psychopharmacology

0 references

219

0 references

3

0 references

715-25

0 references

https://scigraph.springernature.com/pub.10.1007/s00213-011-2393-2

0 references

Training raters to assess adult ADHD: reliability of ratings

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Quantitative morphology of the corpus callosum in attention deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Brain morphology in developmental dyslexia and attention deficit disorder/hyperactivity.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Nicotine effects on adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Cerebral glucose metabolism in adults with hyperactivity of childhood onset

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2393-2

21 January 2018

Transdermal nicotine effects on attention

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attention deficit-hyperactivity disorder and asymmetry of the caudate nucleus

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21748252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-011-2393-2

0 references

Dimensions Publication ID

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28243031&oldid=1410047533"